Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group B multicomponent recombinant vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Meningococcal group B multicomponent recombinant vaccines are biologic vaccines designed to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. The two main marketed products are Bexsero and Trumenba. - **Bexsero** is a four-component vaccine containing recombinant proteins factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin binding antigen (NHBA), and outer membrane vesicles (OMV) from *N. meningitidis*[1][5]. - **Trumenba** contains two variants of the fHbp protein, targeting both subfamilies A and B[4][8]. The mechanism of action involves stimulating the immune system to produce antibodies against these surface proteins, leading to complement-mediated antibody-dependent killing of *N. meningitidis*[1][8]. These antibodies confer protection by targeting key virulence factors required for bacterial survival and invasion. These vaccines are indicated for prevention of invasive disease caused by serogroup B *N. meningitidis* in individuals aged 10–25 years[7].
- Brand names
- BexseroTrumenba
- Other names
- meningococcal group B vaccineMenB vaccine
02
Targets
NadA (Neisserial adhesin A)MenB OMV (Neisseria meningitidis serogroup B outer membrane vesicle)fHbp (Factor H-binding protein)NHBA (Neisserial heparin-binding antigen)PorA
Beyond the preview
Go deeper on meningococcal group B multicomponent recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group B multicomponent recombinant vaccine.